SOPHiA GENETICS Publishes Results of 2022 Annual General Meeting
BOSTON and LAUSANNE, Switzerland, June 15, 2022 /PRNewswire/ — SOPHiA GENETICS SA (Nasdaq: SOPH) (“the Company“), is pleased to announce
Read MoreBOSTON and LAUSANNE, Switzerland, June 15, 2022 /PRNewswire/ — SOPHiA GENETICS SA (Nasdaq: SOPH) (“the Company“), is pleased to announce
Read MoreMUMBAI, India, May 9, 2022 /PRNewswire/ — Datar Cancer Genetics (“Datar”), a world-leading cancer research corporation today announced a $250 million
Read MoreBOSTON and LAUSANNE, Switzerland, May 5, 2022 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, today announced the nomination
Read MoreBOSTON and LAUSANNE, Switzerland, April 26, 2022 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, has reached the
Read MoreThe intended collaboration aims to help improve patient care by enhancing next-generation sequencing research for cancer care and expanding data
Read MoreBOSTON, LAUSANNE, Switzerland and TAIPEI CITY, Taiwan, March 9, 2022 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH) today announced that SOFIVA GENOMICS,
Read MoreThe SOPHiA DDM HRD Solution offers cost-effective, accurate, reliable, timely, and easily implementable in-house results to empower better clinical research
Read MoreIt is the first blood test able to detect early-stage Prostate Cancer with high accuracy in men aged 55 years
Read MoreIt is the first Circulating Tumor Cell detection blood test which is able to identify early-stage Prostate Cancer with high
Read MoreBOSTON and LAUSANNE, Switzerland, Jan. 26, 2022 /PRNewswire/ — SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge
Read More